Identification

Name
Hydroxyzine
Accession Number
DB00557  (APRD00688)
Type
Small Molecule
Groups
Approved
Description

A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite cetirizine, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative. [PubChem]

Structure
Thumb
Synonyms
  • Hidroxizina
  • Hychotine
  • Hydroksyzyny
  • Hydroxine
  • Hydroxizine
  • Hydroxizinum
  • Hydroxycine
  • Hydroxyzin
  • Hydroxyzine
  • Hydroxyzinum
Product Ingredients
IngredientUNIICASInChI Key
Hydroxyzine hydrochloride76755771U32192-20-3ANOMHKZSQFYSBR-UHFFFAOYSA-N
Hydroxyzine pamoateM20215MUFR10246-75-0ASDOKGIIKXGMNB-UHFFFAOYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Atarax Cap 10mgCapsule10 mgOralErfa Canada 2012 Inc1956-12-312005-09-15Canada
Atarax Cap 25mgCapsule25 mgOralErfa Canada 2012 Inc1956-12-312005-09-15Canada
Atarax Cap 50mgCapsule50 mgOralErfa Canada 2012 Inc1959-12-312005-09-15Canada
Atarax Im Sol 50mg/mlSolution50 mgIntramuscularErfa Canada 2012 Inc1957-12-312005-08-18Canada
Atarax Syrup 2mg/mlSyrup10 mgOralErfa Canada 2012 Inc1956-12-31Not applicableCanada
Hydroxyzine Hydrochloride InjectionLiquid50 mgIntramuscularFresenius Kabi2001-04-05Not applicableCanada
Hydroxyzine Hydrochloride Injection USPLiquid50 mgIntramuscularSandoz Canada Incorporated1987-12-31Not applicableCanada
Hydroxyzine Hydrochloride Injection, USPSolution50 mgIntramuscularSterimax Inc1997-05-16Not applicableCanada
Hydroxyzine-10Capsule10 mgOralPro Doc Limitee1987-12-312014-07-24Canada
Hydroxyzine-25Capsule25 mgOralPro Doc Limitee1987-12-312014-07-24Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Hydroxyzine Cap 10mgCapsule10 mgOralApotex Corporation1986-12-31Not applicableCanada
Apo Hydroxyzine Cap 25mgCapsule25 mgOralApotex Corporation1986-12-31Not applicableCanada
Apo Hydroxyzine Cap 50mgCapsule50 mgOralApotex Corporation1986-12-31Not applicableCanada
Hydoxyzine PamoateCapsule25 mg/1OralPd Rx Pharmaceuticals, Inc.1981-12-14Not applicableUs
HydroxyzineTablet, film coated25 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-20Not applicableUs
HydroxyzineTablet, film coated10 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-03-20Not applicableUs
HydroxyzineTablet, film coated10 mg/1OralMajor2007-03-20Not applicableUs
HydroxyzineInjection, solution25 mg/mLIntramuscularGeneral Injectables & Vaccines2010-03-012017-01-27Us
HydroxyzineInjection, solution50 mg/mLIntramuscularGeneral Injectables & Vaccines2010-03-01Not applicableUs
HydroxyzineInjection, solution50 mg/mLIntramuscularGeneral Injectables & Vaccines2010-03-01Not applicableUs
International/Other Brands
Atarax (UCB) / Hyzine (Hyrex) / Masmoran (Pfizer) / Rezine / Vistaject-50 / Vistazine
Categories
UNII
30S50YM8OG
CAS number
68-88-2
Weight
Average: 374.904
Monoisotopic: 374.176105825
Chemical Formula
C21H27ClN2O2
InChI Key
ZQDWXGKKHFNSQK-UHFFFAOYSA-N
InChI
InChI=1S/C21H27ClN2O2/c22-20-8-6-19(7-9-20)21(18-4-2-1-3-5-18)24-12-10-23(11-13-24)14-16-26-17-15-25/h1-9,21,25H,10-17H2
IUPAC Name
2-(2-{4-[(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)ethan-1-ol
SMILES
OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1

Pharmacology

Indication

For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria.

Structured Indications
Pharmacodynamics

Hydroxyzine, a piperazine antihistamine structurally related to buclizine, cyclizine, and meclizine, is used to treat histamine-mediated pruritus or pruritus due to allergy, nausea and vomiting, and, in combination with an opiate agonist, anxiolytic pain. Hydroxyzine is also used as a perioperative sedative and anxiolytic and to manage acute alcohol withdrawal. Hydroxyzine's active metabolite, cetirizine, is also used as an H1-antagonist.

Mechanism of action

Hydroxyzine competes with histamine for binding at H1-receptor sites on the effector cell surface, resulting in suppression of histaminic edema, flare, and pruritus. The sedative properties of hydroxyzine occur at the subcortical level of the CNS. Secondary to its central anticholinergic actions, hydroxyzine may be effective as an antiemetic.

TargetActionsOrganism
AHistamine H1 receptor
antagonist
Human
Absorption

Rapidly absorbed from the gastrointestinal tract

Volume of distribution
Not Available
Protein binding

93%

Metabolism

Hepatic

Route of elimination
Not Available
Half life

20 to 25 hours

Clearance
Not Available
Toxicity

Oral, rat LD50: 950 mg/kg. Symptoms of overexposure include hypersedation.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Hydroxyzine H1-Antihistamine ActionDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Hydroxyzine.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may decrease the sedative activities of Hydroxyzine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Hydroxyzine.Experimental, Illicit
7-NitroindazoleHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.Experimental
AcepromazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.Approved, Vet Approved
AceprometazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.Approved
AdipiplonHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Adipiplon.Investigational
AgomelatineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Alaproclate.Experimental
AlfaxaloneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.Vet Approved
AlfentanilHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.Approved, Illicit
AllopregnanoloneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Allopregnanolone.Investigational
AlphacetylmethadolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine.Illicit
AlprazolamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.Approved, Illicit, Investigational
AmiodaroneHydroxyzine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.Approved, Investigational
AmitriptylineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.Approved
AmobarbitalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.Approved, Illicit
AmoxapineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.Approved
AmperozideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Amperozide.Experimental
AmphetamineAmphetamine may decrease the sedative activities of Hydroxyzine.Approved, Illicit
AnagrelideHydroxyzine may increase the QTc-prolonging activities of Anagrelide.Approved
AripiprazoleHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.Approved, Investigational
Arsenic trioxideHydroxyzine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherHydroxyzine may increase the QTc-prolonging activities of Artemether.Approved
ArticaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Articaine.Approved
AsenapineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Asenapine.Approved
AzaperoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Azaperone.Investigational, Vet Approved
AzelastineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzithromycinHydroxyzine may increase the QTc-prolonging activities of Azithromycin.Approved
BaclofenHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Baclofen.Approved
BarbexacloneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Barbexaclone.Experimental
BarbitalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Barbital.Illicit
BedaquilineHydroxyzine may increase the QTc-prolonging activities of Bedaquiline.Approved
BenperidolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Benperidol.Investigational
BenzocaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.Approved
BenzphetamineBenzphetamine may decrease the sedative activities of Hydroxyzine.Approved, Illicit
Benzyl alcoholHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.Approved
Benzylpenicilloyl PolylysineHydroxyzine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BetahistineThe therapeutic efficacy of Betahistine can be decreased when used in combination with Hydroxyzine.Approved
BrexpiprazoleHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.Approved
BrimonidineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Brimonidine.Approved
BromazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.Approved, Illicit
BromisovalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bromisoval.Experimental
BromperidolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bromperidol.Investigational
BrompheniramineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.Approved
BrotizolamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.Approved, Investigational, Withdrawn
BupivacaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.Approved, Investigational
BuprenorphineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.Approved, Investigational
ButabarbitalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.Approved, Illicit
ButacaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butacaine.Vet Approved
ButalbitalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butalbital.Approved, Illicit
ButambenHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butamben.Approved
ButethalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butethal.Approved, Illicit
ButorphanolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.Approved, Illicit, Vet Approved
CanertinibHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Canertinib.Investigational
CarbamazepineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.Approved, Investigational
CarbinoxamineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.Approved
CarfentanilHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.Illicit, Investigational, Vet Approved
CarisoprodolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.Approved
CeritinibHydroxyzine may increase the QTc-prolonging activities of Ceritinib.Approved
CetirizineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.Approved
Chloral hydrateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.Approved, Illicit
ChlormezanoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.Approved, Investigational, Withdrawn
ChloroprocaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
ChloroquineHydroxyzine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.Approved
ChlorphentermineChlorphentermine may decrease the sedative activities of Hydroxyzine.Illicit, Withdrawn
ChlorpromazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.Approved, Investigational, Withdrawn
ChlorzoxazoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.Approved
CinchocaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.Approved, Vet Approved
CiprofloxacinHydroxyzine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideHydroxyzine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramHydroxyzine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinHydroxyzine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clemastine.Approved
ClidiniumHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.Approved
ClobazamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clobazam.Approved, Illicit
clomethiazoleHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.Investigational
ClomipramineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.Approved, Vet Approved
ClonazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.Approved, Illicit
ClonidineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clonidine.Approved
ClopenthixolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol.Experimental
ClorazepateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.Approved, Illicit
ClothiapineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clothiapine.Experimental
ClozapineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.Approved
CocaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.Approved, Illicit
CodeineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Codeine.Approved, Illicit
CrizotinibHydroxyzine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.Approved
CyclobenzaprineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.Approved
CyproheptadineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.Approved
DantroleneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.Approved
DapiprazoleHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Dapoxetine.Investigational
DeramciclaneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Deramciclane.Investigational
DesfluraneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Desflurane.Approved
DesipramineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.Approved
DesloratadineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Desvenlafaxine.Approved
DetomidineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Detomidine.Vet Approved
DexbrompheniramineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.Approved
DexmedetomidineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.Approved, Vet Approved
DextroamphetamineDextroamphetamine may decrease the sedative activities of Hydroxyzine.Approved, Illicit
DextromoramideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dezocine.Approved, Investigational
DiazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Diazepam.Approved, Illicit, Vet Approved
Diethyl etherHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Diethyl ether.Experimental
DiethylpropionDiethylpropion may decrease the sedative activities of Hydroxyzine.Approved, Illicit
DifenoxinHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.Approved, Illicit
DihydrocodeineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.Approved, Illicit
DihydroetorphineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.Approved
DiphenhydramineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.Approved
DiphenoxylateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.Approved, Illicit
DisopyramideHydroxyzine may increase the QTc-prolonging activities of Disopyramide.Approved
DixyrazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dixyrazine.Experimental
DofetilideHydroxyzine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronHydroxyzine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneHydroxyzine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DoramectinHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Doramectin.Vet Approved
DoxepinHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.Approved
DoxylamineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.Approved, Vet Approved
DPDPEHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.Approved, Illicit
DronedaroneHydroxyzine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.Approved, Vet Approved
DrotebanolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Duloxetine.Approved
DyclonineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.Approved
EcgonineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.Experimental, Illicit
EcopipamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.Investigational
EfavirenzHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
EliglustatHydroxyzine may increase the QTc-prolonging activities of Eliglustat.Approved
EltanoloneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Eltanolone.Investigational
EnfluraneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Enflurane.Approved, Investigational, Vet Approved
EntacaponeHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.Approved, Investigational
ErythromycinHydroxyzine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramHydroxyzine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
EstazolamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Estazolam.Approved, Illicit
EszopicloneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.Approved
EthanolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.Approved, Illicit, Withdrawn
EthosuximideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.Approved
EthotoinHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.Approved
Ethyl carbamateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.Withdrawn
Ethyl chlorideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethyl chloride.Experimental, Investigational
Ethyl loflazepateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
EthylmorphineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.Approved, Illicit
EtidocaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.Approved
EtifoxineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.Investigational, Withdrawn
EtizolamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Etizolam.Approved
EtomidateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Etoperidone.Withdrawn
EtorphineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Etorphine.Illicit, Vet Approved
EzogabineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.Approved
FelbamateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.Approved
FencamfamineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.Approved, Illicit, Withdrawn
FentanylHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Hydroxyzine.Approved
FexofenadineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.Approved
FlecainideHydroxyzine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.Approved
FluanisoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluanisone.Experimental
FludiazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.Approved, Illicit
FlunarizineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.Approved
FlunitrazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.Approved, Illicit
FluoxetineHydroxyzine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.Approved, Withdrawn
FluphenazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.Approved
FlurazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.Approved, Illicit
FluspirileneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.Approved, Investigational
Fluticasone propionateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.Approved
FluvoxamineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.Approved, Investigational
FosphenytoinHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.Approved
FospropofolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.Approved, Illicit, Investigational
GabapentinHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.Approved, Investigational
Gabapentin EnacarbilHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.Approved
Gadobenic acidHydroxyzine may increase the QTc-prolonging activities of Gadobenic acid.Approved
Gamma Hydroxybutyric AcidHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.Approved, Illicit, Investigational
GemifloxacinHydroxyzine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepefrineGepefrine may decrease the sedative activities of Hydroxyzine.Experimental
GepironeHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Gepirone.Investigational
GlutethimideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.Approved, Illicit
GoserelinHydroxyzine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronHydroxyzine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.Approved, Investigational
HalazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Halazepam.Approved, Illicit, Withdrawn
HaloperidolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.Approved
HalothaneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Halothane.Approved, Vet Approved
HeroinHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Heroin.Approved, Illicit, Investigational
HexobarbitalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Hydroxyzine.Approved, Investigational
HydrocodoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.Approved, Illicit
HydroxyamphetamineHydroxyamphetamine may decrease the sedative activities of Hydroxyzine.Approved
IbutilideHydroxyzine may increase the QTc-prolonging activities of Ibutilide.Approved
IloperidoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.Approved
ImipramineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Indalpine.Investigational, Withdrawn
IndiplonHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Indiplon.Investigational
Iofetamine I-123Iofetamine I-123 may decrease the sedative activities of Hydroxyzine.Approved
IsofluraneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.Approved, Vet Approved
KetamineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.Approved, Vet Approved
KetazolamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.Approved
KetobemidoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.Approved, Investigational
LamotrigineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.Approved, Investigational
LenvatinibHydroxyzine may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideHydroxyzine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevetiracetamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.Approved, Investigational
LevobupivacaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.Approved, Investigational
LevocabastineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.Approved
LevocetirizineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.Approved
LevodopaHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levodopa.Approved
LevofloxacinHydroxyzine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Levomilnacipran.Approved
LevorphanolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.Approved
LidocaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may decrease the sedative activities of Hydroxyzine.Approved, Investigational
LithiumHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lithium.Approved
LofentanilHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.Illicit
LopinavirHydroxyzine may increase the QTc-prolonging activities of Lopinavir.Approved
LoprazolamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Loprazolam.Experimental
LoratadineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Loratadine.Approved
LorazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.Approved
LormetazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.Approved
LoxapineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.Approved
LumefantrineHydroxyzine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.Approved
Magnesium SulfateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Magnesium Sulfate.Approved, Vet Approved
MaprotilineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.Approved
MebicarHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mebicar.Experimental
MeclizineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Meclizine.Approved
MedazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Medazepam.Experimental
MedetomidineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.Vet Approved
MelatoninHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Melperone.Approved, Investigational
MephedroneMephedrone may decrease the sedative activities of Hydroxyzine.Investigational
MephentermineMephentermine may decrease the sedative activities of Hydroxyzine.Approved
MepivacaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.Approved, Vet Approved
MeprobamateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.Approved, Illicit
MeptazinolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.Experimental
MesoridazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.Approved, Investigational
MetaxaloneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.Approved
MethadoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methadone.Approved
Methadyl AcetateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may decrease the sedative activities of Hydroxyzine.Approved, Illicit
MethapyrileneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.Withdrawn
MethaqualoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.Illicit, Withdrawn
MethocarbamolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.Approved, Vet Approved
MethohexitalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methohexital.Approved
MethotrimeprazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.Approved, Investigational, Vet Approved
MethoxyphenamineMethoxyphenamine may decrease the sedative activities of Hydroxyzine.Experimental
MethsuximideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.Approved
MethylecgonineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.Experimental
MethylphenobarbitalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Hydroxyzine.Approved, Investigational
MetyrosineHydroxyzine may increase the sedative activities of Metyrosine.Approved
MidazolamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.Approved, Illicit
MidomafetamineMidomafetamine may decrease the sedative activities of Hydroxyzine.Experimental, Illicit, Investigational
MifepristoneMifepristone may increase the QTc-prolonging activities of Hydroxyzine.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.Approved, Investigational
MirtazapineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MMDAMMDA may decrease the sedative activities of Hydroxyzine.Experimental, Illicit
MolindoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Molindone.Approved
MorphineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Morphine.Approved, Investigational
MoxifloxacinHydroxyzine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NabiloneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nabilone.Approved, Investigational
NalbuphineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Nefazodone.Approved, Withdrawn
NilotinibHydroxyzine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.Approved
Nitrous oxideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.Approved, Vet Approved
NorfluraneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Norflurane.Investigational
NormethadoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Normethadone.Approved, Illicit
NortriptylineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.Approved
OfloxacinHydroxyzine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.Approved, Investigational
OlopatadineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.Approved
OndansetronHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.Approved
OpiumHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Opium.Approved, Illicit
OrphenadrineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.Investigational
OxazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.Approved
OxethazaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxethazaine.Approved, Investigational
OxprenololHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.Approved
OxybuprocaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.Approved
OxycodoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.Approved, Illicit, Investigational
OxymorphoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.Approved, Investigational, Vet Approved
PaliperidoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.Approved
PanobinostatHydroxyzine may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
ParaldehydeHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Paroxetine.Approved, Investigational
PazopanibHydroxyzine may increase the QTc-prolonging activities of Pazopanib.Approved
PenfluridolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Penfluridol.Experimental
PentamidineHydroxyzine may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.Approved, Vet Approved
PentobarbitalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.Approved
PerazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Perazine.Investigational
PerflutrenHydroxyzine may increase the QTc-prolonging activities of Perflutren.Approved
PerospironeHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Perospirone.Approved
PerphenazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.Approved
PethidineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pethidine.Approved
PhenazocineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Phenazocine.Experimental
PhenibutHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Phenibut.Experimental
PhenobarbitalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.Approved
PhenoperidineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Phenoperidine.Experimental
PhenoxyethanolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.Approved
PhenterminePhentermine may decrease the sedative activities of Hydroxyzine.Approved, Illicit
PhenytoinHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.Approved, Vet Approved
PimozideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pimozide.Approved
PipamperoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.Approved, Investigational
PipotiazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.Approved, Investigational
PiritramideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Piritramide.Investigational
PizotifenHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.Approved
PomalidomideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.Approved
PramipexoleHydroxyzine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.Approved
PrazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.Approved, Illicit
PregabalinHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.Approved, Illicit, Investigational
PrilocaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.Approved
PrimaquineHydroxyzine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Primidone.Approved, Vet Approved
ProcainamideHydroxyzine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Procaine.Approved, Investigational, Vet Approved
ProchlorperazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.Approved, Vet Approved
PromazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
PromethazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.Approved
PropafenoneHydroxyzine may increase the QTc-prolonging activities of Propafenone.Approved
PropanididHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Propanidid.Experimental
ProparacaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.Approved, Vet Approved
PropofolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Propofol.Approved, Investigational, Vet Approved
PropoxycaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.Approved
ProtriptylineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.Approved
ProxibarbalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Proxibarbal.Experimental
PSD502Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of PSD502.Investigational
PseudoephedrinePseudoephedrine may decrease the sedative activities of Hydroxyzine.Approved
QuazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Quazepam.Approved, Illicit
QuetiapineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.Approved
QuinidineHydroxyzine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineHydroxyzine may increase the QTc-prolonging activities of Quinine.Approved
QuinisocaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Quinisocaine.Experimental
RacloprideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Raclopride.Investigational
RamelteonHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.Approved, Investigational
RemifentanilHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.Approved
RemoxiprideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.Approved, Withdrawn
ReserpineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Reserpine.Approved, Investigational
RisperidoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.Approved, Investigational
RitanserinHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.Investigational
RitobegronRitobegron may decrease the sedative activities of Hydroxyzine.Investigational
RomifidineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Romifidine.Vet Approved
RopiniroleHydroxyzine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.Approved
RotigotineHydroxyzine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Hydroxyzine.Approved
SaquinavirHydroxyzine may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.Approved
SecobarbitalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.Approved, Vet Approved
SepranoloneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sepranolone.Investigational
SertindoleHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Sertraline.Approved
SevofluraneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.Approved
SotalolHydroxyzine may increase the QTc-prolonging activities of Sotalol.Approved
StiripentolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.Approved
SufentanilHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
SulfisoxazoleHydroxyzine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SulpirideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.Approved, Investigational
SultoprideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sultopride.Experimental
SuvorexantHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Hydroxyzine.Approved
TasimelteonHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.Approved
TelavancinHydroxyzine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinHydroxyzine may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.Approved
TetrabenazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.Approved
TetracaineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.Approved, Vet Approved
TetrahydropalmatineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.Investigational
TetrodotoxinHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.Investigational
ThalidomideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.Approved, Vet Approved
ThiopentalHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thiopental.Approved, Vet Approved
ThioridazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.Approved, Withdrawn
ThiothixeneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.Approved
TiagabineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.Approved
TiaprideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.Approved, Investigational
TiletamineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.Vet Approved
TilidineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tilidine.Experimental
TizanidineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.Approved
TolcaponeHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.Approved, Withdrawn
TopiramateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.Approved
ToremifeneHydroxyzine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TramadolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.Approved, Investigational
Trans-2-PhenylcyclopropylamineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tranylcypromine.Approved
TrazodoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.Approved, Investigational
TriazolamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Triazolam.Approved
Tricaine methanesulfonateHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Tricaine methanesulfonate.Vet Approved
TrichloroethyleneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trichloroethylene.Experimental
TrifluoperazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.Approved
TrifluperidolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trifluperidol.Experimental
TriflupromazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.Approved, Vet Approved
TrimipramineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.Approved
TriprolidineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.Approved
Valproic AcidHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.Approved, Investigational
VandetanibHydroxyzine may increase the QTc-prolonging activities of Vandetanib.Approved
VemurafenibHydroxyzine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Venlafaxine.Approved
VeraliprideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Veralipride.Experimental
VigabatrinHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.Approved
Vinyl etherHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Vinyl ether.Experimental
VortioxetineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
XenonHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Xenon.Experimental
XylazineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Hydroxyzine can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.Approved, Illicit, Investigational
ZiconotideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Hydroxyzine is combined with Zimelidine.Withdrawn
ZiprasidoneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.Approved
ZolazepamHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.Vet Approved
ZolpidemHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.Approved, Investigational
ZopicloneHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.Approved
ZotepineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zotepine.Approved, Investigational
ZuclopenthixolHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Take with food.

References

Synthesis Reference

U.S. Patent 2,899,436.

General References
  1. HUTCHEON DE, MORRIS DL, SCRIABINE A: Cardiovascular action of hydroxyzine (atarax). J Pharmacol Exp Ther. 1956 Dec;118(4):451-60. [PubMed:13385806]
  2. DOLAN CM: Management of emotional disturbances; use of hydroxyzine (atarax) in general practice. Calif Med. 1958 Jun;88(6):443-4. [PubMed:13536863]
  3. Clark BG, Araki M, Brown HW: Hydroxyzine-associated tardive dyskinesia. Ann Neurol. 1982 Apr;11(4):435. [PubMed:7103423]
External Links
Human Metabolome Database
HMDB14697
KEGG Compound
C07045
PubChem Compound
3658
PubChem Substance
46508556
ChemSpider
3531
BindingDB
22875
ChEBI
5818
ChEMBL
CHEMBL896
Therapeutic Targets Database
DAP000324
PharmGKB
PA449943
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Hydroxyzine
ATC Codes
N05BB51 — Hydroxyzine, combinationsN05BB01 — Hydroxyzine
AHFS Codes
  • 28:24.92 — Miscellaneous Anxiolytics Sedatives and Hypnotics
MSDS
Download (73.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedNot AvailableFeeling Anxious1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depression / Psychosomatic Disorders / Schizophrenic Disorders1
4CompletedBasic ScienceHealthy Volunteers1
4CompletedPreventionNausea / Pruritus / Vomiting1
4CompletedTreatmentPain1
4Not Yet RecruitingTreatmentFeeling Anxious1
4TerminatedPreventionHealthy Volunteers1
4WithdrawnTreatmentAnxiety in Those Patients With Anorexia Nervosa / Anxiety in Those Patients With Anorexia Nervosa or Eating Disorder Not Otherwise Specified, Specifically With Low BMI(≤ 18) / Eating Disorder Not Otherwise Specified, BMI (<=18)1
Not AvailableCompletedBasic SciencePlacebo Drug Interaction / Placebo Effect1
Not AvailableCompletedTreatmentSubstance-Related Disorders1

Pharmacoeconomics

Manufacturers
  • Baxter healthcare corp anesthesia and critical care
  • Altana inc
  • App pharmaceuticals llc
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Pharmafair inc
  • Smith and nephew solopak div smith and nephew
  • Solopak medical products inc
  • Solopak laboratories inc
  • Watson laboratories inc
  • Wyeth ayerst laboratories
  • Organon usa inc
  • Pfizer laboratories div pfizer inc
  • Roerig div pfizer inc
  • Actavis mid atlantic llc
  • Alpharma us pharmaceuticals division
  • Hi tech pharmacal co inc
  • Kv pharmaceutical co
  • Vintage pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Pfizer inc
  • Able laboratories inc
  • Actavis totowa llc
  • Amneal pharmaceutical
  • Halsey drug co inc
  • Heritage pharmaceuticals inc
  • Hetero drugs ltd unit iii
  • Invagen pharmaceuticals inc
  • Ivax pharmaceuticals inc
  • Kvk tech inc
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Northstar healthcare holdings ltd
  • Pliva inc
  • Purepac pharmaceutical co
  • Quantum pharmics ltd
  • Sandoz inc
  • Sun pharmaceutical industries inc
  • Superpharm corp
  • Usl pharma inc
  • Vintage pharmaceuticals llc
  • Barr laboratories inc
  • Duramed pharmaceuticals inc sub barr laboratories inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Par pharmaceutical inc
  • Vangard laboratories inc div midway medical co
  • Teva pharmaceuticals usa inc
Packagers
Dosage forms
FormRouteStrength
CapsuleOral10 mg
CapsuleOral25 mg
CapsuleOral50 mg
SolutionIntramuscular50 mg
Injection, solutionIntramuscular25 mg/mL
Injection, solutionIntramuscular50 mg/mL
SolutionOral10 mg/5mL
SyrupOral10 mg/5mL
TabletOral10 mg/1
TabletOral25 mg/1
TabletOral50 mg/1
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral50 mg/1
LiquidIntramuscular50 mg
CapsuleOral100 mg/1
CapsuleOral25 mg/1
CapsuleOral50 mg/1
SyrupOral10 mg
SolutionIntramuscular50 mg/mL
Prices
Unit descriptionCostUnit
Hydroxyzine Hcl 50 mg/ml4.42USD ml
Hydroxyzine 50 mg/ml vial3.96USD ml
Hydroxyzine 25 mg/ml vial3.6USD ml
Hydroxyzine hcl powder2.75USD g
Hydroxyzine pamoate powder2.14USD g
Vistaril 50 mg capsule2.03USD capsule
HydrOXYzine HCl 50 mg/ml vial1.78USD vial
Vistaril 25 mg capsule1.71USD capsule
Vistaril 100 mg capsule1.7USD capsule
Hydroxyzine hcl 50 mg tablet1.19USD tablet
Hydroxyzine hcl 10 mg tablet0.72USD tablet
Hydroxyzine hcl 25 mg tablet0.7USD tablet
HydrOXYzine Pamoate 100 mg capsule0.67USD capsule
Hydroxyzine pam 50 mg capsule0.64USD capsule
Hydroxyzine pam 100 mg capsule0.63USD capsule
Hydroxyzine pam 25 mg capsule0.46USD capsule
Vistaril 25 mg/5ml Suspension0.45USD ml
HydrOXYzine Pamoate 25 mg capsule0.3USD capsule
HydrOXYzine Pamoate 50 mg capsule0.23USD capsule
Apo-Hydroxyzine 50 mg Capsule0.22USD capsule
Novo-Hydroxyzin 50 mg Capsule0.22USD capsule
Apo-Hydroxyzine 25 mg Capsule0.15USD capsule
Novo-Hydroxyzin 25 mg Capsule0.15USD capsule
HydrOXYzine HCl 10 mg/5ml Syrup0.13USD ml
Apo-Hydroxyzine 10 mg Capsule0.12USD capsule
Novo-Hydroxyzin 10 mg Capsule0.12USD capsule
Atarax 2 mg/ml Syrup0.06USD ml
Pms-Hydroxyzine 2 mg/ml Syrup0.04USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)193 °CU.S. Patent 2,899,436.
water solubility< 700 mg/mLNot Available
logP2.7Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0914 mg/mLALOGPS
logP3.43ALOGPS
logP3.41ChemAxon
logS-3.6ALOGPS
pKa (Strongest Acidic)15.12ChemAxon
pKa (Strongest Basic)7.82ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area35.94 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity107.07 m3·mol-1ChemAxon
Polarizability41.99 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.8623
Blood Brain Barrier+0.9516
Caco-2 permeable-0.5565
P-glycoprotein substrateSubstrate0.7447
P-glycoprotein inhibitor IInhibitor0.8563
P-glycoprotein inhibitor IIInhibitor0.6394
Renal organic cation transporterInhibitor0.592
CYP450 2C9 substrateNon-substrate0.8352
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7193
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9111
CYP450 2D6 inhibitorInhibitor0.8535
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9623
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7615
Ames testNon AMES toxic0.7558
CarcinogenicityNon-carcinogens0.9102
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.6612 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5929
hERG inhibition (predictor II)Inhibitor0.7898
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0udi-6491000000-95c46c16c2b29900f4d9
Mass Spectrum (Electron Ionization)MSsplash10-0uxr-4591000000-d2e3424c44feae8a5d9c
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0593000000-f20d2328497a3a80239b

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
N-alkylpiperazines / Chlorobenzenes / Aralkylamines / Aryl chlorides / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Primary alcohols / Organopnictogen compounds / Organochlorides
show 1 more
Substituents
Diphenylmethane / Chlorobenzene / Aralkylamine / Halobenzene / N-alkylpiperazine / Aryl chloride / Aryl halide / 1,4-diazinane / Piperazine / Tertiary aliphatic amine
show 17 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monochlorobenzenes, N-alkylpiperazine, hydroxyether (CHEBI:5818)

Targets

Details
1. Histamine H1 receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Histamine receptor activity
Specific Function
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name
HRH1
Uniprot ID
P35367
Uniprot Name
Histamine H1 receptor
Molecular Weight
55783.61 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Spahr L, Coeytaux A, Giostra E, Hadengue A, Annoni JM: Histamine H1 blocker hydroxyzine improves sleep in patients with cirrhosis and minimal hepatic encephalopathy: a randomized controlled pilot trial. Am J Gastroenterol. 2007 Apr;102(4):744-53. Epub 2007 Jan 11. [PubMed:17222324]
  3. Sakaguchi T, Itoh H, Ding WG, Tsuji K, Nagaoka I, Oka Y, Ashihara T, Ito M, Yumoto Y, Zenda N, Higashi Y, Takeyama Y, Matsuura H, Horie M: Hydroxyzine, a first generation H(1)-receptor antagonist, inhibits human ether-a-go-go-related gene (HERG) current and causes syncope in a patient with the HERG mutation. J Pharmacol Sci. 2008 Dec;108(4):462-71. Epub 2008 Dec 5. [PubMed:19057127]
  4. Chen C: Physicochemical, pharmacological and pharmacokinetic properties of the zwitterionic antihistamines cetirizine and levocetirizine. Curr Med Chem. 2008;15(21):2173-91. [PubMed:18781943]
  5. Snowman AM, Snyder SH: Cetirizine: actions on neurotransmitter receptors. J Allergy Clin Immunol. 1990 Dec;86(6 Pt 2):1025-8. [PubMed:1979798]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Hamelin BA, Bouayad A, Drolet B, Gravel A, Turgeon J: In vitro characterization of cytochrome P450 2D6 inhibition by classic histamine H1 receptor antagonists. Drug Metab Dispos. 1998 Jun;26(6):536-9. [PubMed:9616188]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34